Cargando…

Author's overview: identifying SARS-CoV-2 antiviral compounds

In response to the COVID-19 pandemic, we began a project in March 2020 to identify small molecule inhibitors of SARS-CoV-2 enzymes from a library of chemical compounds containing many established pharmaceuticals. Our hope was that inhibitors we found might slow the replication of the SARS-CoV-2 viru...

Descripción completa

Detalles Bibliográficos
Autor principal:	Diffley, John F.X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286811/ https://www.ncbi.nlm.nih.gov/pubmed/34198320 http://dx.doi.org/10.1042/BCJ20210426

Ejemplares similares

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease
por: Canal, Berta, et al.
Publicado: (2021)

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase
por: Zeng, Jingkun, et al.
Publicado: (2021)

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase
por: Bertolin, Agustina P., et al.
Publicado: (2021)

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease
por: Canal, Berta, et al.
Publicado: (2021)

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease
por: Milligan, Jennifer C., et al.
Publicado: (2021)

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease
por: Lim, Chew Theng, et al.
Publicado: (2021)

Unchecked nick ligation can promote localized genome re-replication
por: Johansson, Erik, et al.
Publicado: (2021)

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase
por: Basu, Souradeep, et al.
Publicado: (2021)

SARS-CoV-2 seroprevalence in Spain – Authors' reply
por: Pollán, Marina, et al.
Publicado: (2020)

SARS-CoV-2 infection in conjunctival tissue – Authors' reply
por: Hui, Kenrie PY, et al.
Publicado: (2020)

Neuropathology associated with SARS-CoV-2 infection – Authors' reply
por: von Weyhern, Claus Hann, et al.
Publicado: (2021)

SARS-CoV-2 serological cross-reactivity with autoantibodies – Authors' reply
por: Teng, Jialin, et al.
Publicado: (2021)

Stability of SARS-CoV-2 in different environmental conditions – Authors' reply
por: Chin, Alex W H, et al.
Publicado: (2020)

Transmission of SARS-CoV-2: still up in the air – Authors' reply
por: Greenhalgh, Trisha, et al.
Publicado: (2022)

Practical measures for SARS-CoV-2 infection prevention – Authors' reply
por: Llibre, Josep M, et al.
Publicado: (2022)

SARS-CoV-2 rapid antigen detection tests – Authors' reply
por: Peeling, Rosanna W, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 in Hong Kong returnees – Authors' reply
por: To, Kelvin Kai-Wang, et al.
Publicado: (2020)

Challenges and issues of SARS-CoV-2 pool testing – Authors' reply
por: Lohse, Stefan, et al.
Publicado: (2020)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Serological assays for delayed SARS-CoV-2 case identification – Author's reply
por: Pallett, Scott J C, et al.
Publicado: (2020)

Neutrophils as a pallbearer for SARS-CoV-2 disease burden – Authors’ reply
por: Lutter, René, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran – Authors' reply
por: Darvishian, Maryam, et al.
Publicado: (2021)

Unclear conclusions on SARS-CoV-2 elimination versus mitigation – Authors' reply
por: Oliu-Barton, Miquel, et al.
Publicado: (2021)

Bell's palsy and SARS-CoV-2 vaccines—an unfolding story – Authors' reply
por: Ozonoff, Al, et al.
Publicado: (2021)

SARS-CoV-2 vaccination for patients with inflammatory bowel disease – Authors' reply
por: Alexander, James L, et al.
Publicado: (2021)

Transmissibility of SARS-CoV-2 among fully vaccinated individuals – Authors' reply
por: Lalvani, Ajit, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors' reply
por: Voysey, Merryn, et al.
Publicado: (2020)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

Cyclosporin A Reveals Potent Antiviral Effects in Preclinical Models of SARS-CoV-2 Infection
por: Sauerhering, Lucie, et al.
Publicado: (2022)

Association of SARS-CoV-2 renal tropism with acute kidney injury – Authors' reply
por: Braun, Fabian, et al.
Publicado: (2020)

The ability of the neonatal immune response to handle SARS-CoV-2 infection – Authors' reply
por: Gale, Chris, et al.
Publicado: (2021)

Is oropharyngeal sampling a reliable test to detect SARS-CoV-2? – Authors' reply
por: Tsang, Nicole Ngai Yung, et al.
Publicado: (2021)

Misclassification bias in estimating clinical severity of SARS-CoV-2 variants – Authors' reply
por: Nyberg, Tommy, et al.
Publicado: (2022)

An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2 – Authors' reply
por: Keusch, Gerald T, et al.
Publicado: (2021)

Misuse of SARS-CoV-2 testing in symptomatic health-care staff in the UK – Authors' reply
por: Black, James R M, et al.
Publicado: (2020)

Specificity and cross-reactivity of a test for anti-SARS-CoV-2 antibodies – Authors' reply
por: Iversen, Kasper, et al.
Publicado: (2021)

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

The proximal origin of SARS-CoV-2
por: Andersen, Kristian G., et al.
Publicado: (2020)

Neuropathology associated with SARS-CoV-2 infection
por: Egervari, Kristof, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fqe0tlkgrmda7iic3gc9hqrilb